Mortality predictors of Pneumocystis jirovecii pneumonia in human immunodeficiency virus-infected patients at presentation: Experience in a tertiary care hospital of northern Taiwan

Wang, Hsiao-Wei; Lin, Cheng-Chih; Kuo, Chen-Feng; Liu, Chang-Pan; Lee, Chun-Ming

doi:10.1016/j.jmii.2010.08.006

Cited by 32 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When CXR is at the mid stage, chest CT may be at the early- or mid-stage. In the mid stage, the patients usually present with obvious dyspnea and hypoxemia,[13] and then clinicians just recognize the diagnosis of PCP, although PCP in patients without AIDS was diagnosed after a shorter time interval from symptom onset. [8] Our study showed that the CFR of PCP is significantly higher when specific anti-PCP treatments begin in the mid stage rather than early stage.…”

Section: Discussionmentioning

confidence: 99%

Relationship between Radiological Stages and Prognoses of Pneumocystis Pneumonia in Non-AIDS Immunocompromised Patients

Jia

Gao

et al. 2016

Chinese Medical Journal

View full text Add to dashboard Cite

Background:Although radiological features of pneumocystis pneumonia (PCP) in non-Acquired Immune Deficiency Syndrome (AIDS) immunocompromised patients have been reported by other authors, there were no studies on the radiological stages of PCP previously. This study aimed to elucidate the radiological stages and prognoses of PCP in non-AIDS immunocompromised patients.Methods:Retrospective analysis of radiological manifestations and prognoses of 105 non-AIDS PCP immunocompromised patients from August 2009 to April 2016 was conducted. Chest radiograph was divided into three stages: early stage (normal or nearly normal chest radiograph), mid stage (bilateral pulmonary infiltrates), and late stage (bilateral pulmonary consolidations); chest high-resolution computed tomography (HRCT) was also divided into three stages: early stage (bilateral diffuse ground-glass opacity [GGO]), mid stage (bilateral diffuse GGO and patchy consolidations), and late stage (bilateral diffuse consolidations).Results:The case fatality rate (CFR) of all patients was 34.3% (36/105), all of them took routine chest X-ray (CXR), and 84 underwent chest CT examinations. According to the CXR most near the beginning of anti-PCP therapy, 18 cases were at early stage and CFR was 0 (0/18, P < 0.01), 50 cases were at mid stage and CFR was 28.0% (14/50, P > 0.05), and 37 cases were at late stage and CFR was 59.5% (22/37, P < 0.01). According to the chest HRCT most near the beginning of anti-PCP therapy, 40 cases were at early stage and CFR was 20.0% (8/40, P > 0.05), 34 cases were at mid stage and CFR was 47.1% (16/34, P > 0.05), and 10 cases were at late stage and CFR was 80.0% (8/10, P < 0.05); barotrauma, including pneumothorax, pneumomediastinum, and pneumohypoderma, was found in 18 cases and the CFR was 77.8% (14/18, P < 0.01).Conclusions:Based on the radiological manifestations, the course of PCP in non-AIDS immunocompromised patients can be divided into three stages: early stage, mid stage, and late stage. The prognoses of patients treated at early stage are good, and those at late stage are poor. Furthermore, the CFR of patients with barotrauma is high.

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship between Radiological Stages and Prognoses of Pneumocystis Pneumonia in Non-AIDS Immunocompromised Patients

Jia

Gao

et al. 2016

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

“…An association of this comorbidity factor with an increased risk for death has already been reported ( 24 , 25 ). Several other clinical parameters were reported to be predictors for death caused by PCP in HIV-infected patients ( 26 ), and a scoring tool was recently proposed ( 27 ). Host polymorphisms within receptors involved in the immune response have also been reported to be related to P. jirovecii infection ( 28 , 29 ).…”

Section: Discussionmentioning

confidence: 99%

Pneumocystis jiroveciiGenotype Associated with Increased Death Rate of HIV-infected Patients with Pneumonia

Rabodonirina¹,

Vaillant²,

Taffé³

et al. 2013

Emerg. Infect. Dis.

View full text Add to dashboard Cite

show abstract

“…The most common cause of death remains to be PJP, a preventable disease if HAART with/without PJP prophylaxis is initiated early enough [1,3]. Despite good adherence to PJP treatment guidelines, mortality rates remain high, between 35-40% [15,16].…”

Section: Discussionmentioning

confidence: 99%

High Rates of Fatality Due to AIDS without Universal HIV Testing

Bassi¹,

Bland

Martin

2014

J AIDS Clin Res

View full text Add to dashboard Cite

show abstract

Mortality predictors of Pneumocystis jirovecii pneumonia in human immunodeficiency virus-infected patients at presentation: Experience in a tertiary care hospital of northern Taiwan

Abstract: HIV-infected patients with PJP can be clinically stratified by three prognostic variables identified by multivariate analysis. Early recognition of patients in higher risk can assist clinicians to prevent rapid deterioration and seek for better outcomes.

Cited by 32 publications

References 30 publications

Relationship between Radiological Stages and Prognoses of Pneumocystis Pneumonia in Non-AIDS Immunocompromised Patients

Relationship between Radiological Stages and Prognoses of Pneumocystis Pneumonia in Non-AIDS Immunocompromised Patients

Pneumocystis jiroveciiGenotype Associated with Increased Death Rate of HIV-infected Patients with Pneumonia

High Rates of Fatality Due to AIDS without Universal HIV Testing

Contact Info

Product

Resources

About